Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188853 | 0.91 | KMT2A (0.64) | KMT2AMEN1RIPK1CYP2D6POLB | |
| SCHEMBL27699066 | 0.90 | KMT2A (0.62) | KMT2AMEN1RIPK1CYP2D6POLB | |
| SCHEMBL3261770 | 0.88 | MAPT (0.51) | KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL3261165 | 0.85 | CYP1A2 (0.54) | KMT2AMEN1RIPK1CYP2D6POLB | |
| SCHEMBL23794658 | 0.85 | GAA (0.51) | KMT2AMEN1CYP2D6CYP2C19GAA | |
| SCHEMBL18821265 | 0.85 | GAA (0.51) | KMT2AMEN1CYP2D6CYP2C19GAA | |
| SCHEMBL18821249 | 0.85 | GAA (0.51) | KMT2AMEN1CYP2D6CYP2C19GAA | |
| SCHEMBL8296543 | 0.84 | CYP3A4 (0.50) | KMT2AMEN1CYP2D6POLBCYP2C9 | |
| SCHEMBL3183843 | 0.83 | KDM4E (0.49) | KMT2AMEN1RIPK1GAAHPGD | |
| SCHEMBL24992399 | 0.81 | KMT2A (0.61) | KMT2AMEN1RIPK1CYP2D6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150265613-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8993632-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2835367-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | AbbVie Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20120289512-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
| US-8198331-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-06-12 | — | — | US | disclosed |
| US-RE41135-E1 | Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-7528282-B2 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBOTT LABORATORIES (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | HSD17B1, HSD3B1, HSD17B2 | KMT2A 1782/4885MEN1 2445/4885RIPK1 3297/4885 |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | HSD17B1, HSD11B1, HSD3B1 | KMT2A 2894/4885MEN1 2738/4885RIPK1 3471/4885 |
| US-20150265613-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | KMT2A 2398/4885MEN1 1903/4885RIPK1 3542/4885 |
| US-20120289512-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD11B2, HSD17B1 | KMT2A 2398/4885MEN1 1903/4885RIPK1 3542/4885 |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | KMT2A 2398/4885MEN1 1903/4885RIPK1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.